孟鲁司特治疗病毒感染婴幼儿喘息的临床研究

Clinical research of Montelukast on treatment of wheezing infantile with virus infection

目的 观察孟鲁司特治疗病毒感染婴幼儿喘息的临床疗效.方法 选取2011年3月-2012年3月收治的病毒性感染所致喘息患儿共142例,随机分为观察组70例和对照组72例,对照组患儿采用常规抗病毒、雾化吸入及对症治疗,喘息严重的患儿给予甲基强的松龙2mg/kg·次,每天1-2次静脉滴注.观察组在上述治疗基础上加服孟鲁司特,超过1岁的患儿每次给予4mg,每晚顿服;＜1岁的患儿则隔日服药,每次同样给予4mg,治疗7后天比较疗效.结果 观察组患儿的治疗有效率为87.1％,明显高于对照组的73.6％（P＜0.05）;观察组治愈的患儿占37.1％,明显高于对照组的15.3％（P＜0.05）;观察组患儿的咳喘消失时间[（6.1±0.7）d]和肺部啰音消失时间[（5.4±0.7）d）]均明显短于时照组[（7.2±1.2）d、（6.4±1.0）d,P＜0.05].另外,观察组需要使用全身性激素超过3天的病例只有11例,明显少于对照组的24例（P＜0.05）;观察组患儿的住院时间[（6.9±1.6）d]也明显短于对照组[（7.8±1.3）d,P＜0.05].结论 孟鲁斯特用于病毒性感染合并喘息的婴幼儿,可以明显提高治疗有效率和治愈率,缩短临床症状改善时间和患儿住院时间,同时还可以减少全身性激素使用时间,提高治疗的安全性,值得临床推广应用.

Objective To observe the clinical effect of montelukast on treatment of wheezing infantile with virus infection.Methods 142 wheezing infants with virus infection were randomly divided into the observation group （70 cases） and control group （72 cases）.The control groups was treated with conventional antivirus,atomization inhalation,symptomatic treatment and methylpred-nisolone.The observation group was treated with the methods of the control group and montelulzas.Results The effective rate of control group and observation group were 73.6％ and 87.1 ％ （P＜0.05）.The cured rates of control group and observation group were 15.3％ and 37.1％ （P＜0.05）.The hospital time of control group and observation group were （7.8±1.3） d and （6.9±1.6） d （P＜0.05）.Conclusion Montelukast can significantly improve the treatment effective rate and cure rate,shorten the time of clinical improvement and the time of hospitalization of wheezing infantile with virus infection.